Table 4.

The relationship of E6 and DNA detection of HPV genotypes 16, 18, and/or 45 (HPV16/18/45) on cervical exfoliated cells with HPV genotypes detected in the tissue of CIN2, CIN3, cervical cancer, CIN2+, and CIN3+ diagnoses

A. Worst, H&E diagnosis
CIN2 (n = 45)CIN3 (n = 86)Cancer (n = 13)CIN2+ (n = 144)CIN3+ (n = 99)
E6DNAE6DNAE6DNAE6DNAE6DNA
nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)
 HPV16+14642.8614100.0614065.575691.8121191.6712100.0875765.528294.25735169.866893.15
 HPV18+5240.0480.0000.000.0000.000.05240.0480.0000.000.0
 HPV45+000.000.011100.0110.0000.000.011100.01100.011100.01100.0
 HPV16/18/45+19842.111894.74624166.135791.94121191.6712100.0936064.528793.55745270.276993.24
 Other carcinogenic2200.014.552000.0315.0000.000.04200.049.62000.0315.0
 Noncarcinogenic300.0133.33200.000.0000.000.0500.0120.0200.000.0
 HPV Negative100.01100.02150.02100.0100.000.04125.0375.03133.33266.67
B. p16-negative
CIN2 (n = 5)CIN3 (n = 11)Cancer (n = 0)CIN2+ (n = 16)CIN3+ (n = 11)
E6DNAE6DNAE6DNAE6DNAE6DNA
nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)
 HPV16+100.01100.07342.86685.7100n/a0n/a8337.5787.57342.86685.71
 HPV18+000.000.0000.000.000n/a0n/a000.000.0000.000.0
 HPV45+000.000.0000.000.000n/a0n/a000.000.0000.000.0
 HPV16/18/45+100.01100.07342.86685.7100n/a0n/a8337.5787.57342.86685.71
 Other carcinogenic300.000.0200.0150.000n/a0n/a500.0120.0200.0150.0
 Noncarcinogenic000.000.0100.000.000n/a0n/a100.000.0100.000.0
 HPV Negative100.01100.011100.01100.000n/a0n/a2150.02100.011100.01100.0
C. p16-positive
CIN2 (n = 40)CIN3 (n = 75)Cancer (n = 13)CIN2+ (n = 128)CIN3+ (n = 88)
E6DNAE6DNAE6DNAE6DNAE6DNA
nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)nn (+)% (+)n (+)% (+)
 HPV16+13646.1513100.0543768.525092.59121191.6712100.0795468.357594.94664872.736293.94
 HPV18+5240.0480.0000.000.0000.000.05240.0480.0000.000.0
 HPV45+000.000.011100.01100.0000.000.011100.01100.011100.01100.0
 HPV16/18/45+18844.441794.44553869.095192.73121191.6712100.0855767.068094.12674973.136394.03
 Other carcinogenic1900.015.261800.0211.11000.000.03700.038.111800.0211.11
 Noncarcinogenic300.0133.33100.000.0000.000.0400.0125.0100.000.0
 HPV Negative000.000.0100.01100.0100.000.0200.0150.0200.0150.0

aHPV16/18/45 E6 was detected by the AVantage HPV E6 test and HPV16/18/45 DNA was detected by a research-use only probe set developed for the careHPV platform and used only among the careHPV-positive women (data for the clinician-collected specimens only). The results of the HPV genotyping of the tissues were hierarchically categorized according to cancer risk to handle rare circumstances in which multiple HPV genotypes were detected: HPV16 > HPV18 > HPV45 > other carcinogenic HPV genotypes (HPV31, 33, 35, 39, 51, 52, 56, 58, 59, or 68) > noncarcinogenic HPV genotypes (including HPV positive with no HPV genotype identified)> HPV negative. The results are present for all diagnoses and stratified on whether the tissue tested p16INK4a positive by immunohistochemistry.